DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Caribou - 1 NASH - 1 Jennifer Doudna - 1 Raghav Mahobe - 1 Leroy Leo - 1 Maju Samuel - 1
Top related locs:
Caribou California Bengaluru
Top related orgs:
Pfizer - 1 Caribou Biosciences - 1 Biohaven Pharmaceutical - 1 Akero Therapeutics - 1 Thomson - 1

Search resuls for: "Biohaven Pharmaceutical"


8 mentions found


☆ Pfizer makes equity investment in Caribou Biosciences
  + stars: | 2023-07-06 | by ( ) www.reuters.com   time to read: +2 min
July 6 (Reuters) - Pfizer (PFE.N) has invested $25 million to buy a minority stake in Caribou Biosciences (CRBU.O), making it the latest small biotechnology firm to attract the pharmaceutical giant's interest. The news lifted shares of Caribou more than 61% in early trade. Pfizer purchased nearly 4.7 million Caribou shares at $5.33 per share, Caribou said on Thursday, representing a premium of about 30% over Caribou's previous close price. This represents 7.64% of outstanding shares in Caribou, according to Reuters' calculation based on Refinitiv IBES data. It also made a $25 million equity investment in Akero Therapeutics (AKRO.O) last year.
Persons: Caribou, NASH, Jennifer Doudna, Raghav Mahobe, Leroy Leo, Maju Samuel Organizations: Pfizer, Caribou Biosciences, Biohaven Pharmaceutical, Akero Therapeutics, Thomson Locations: Caribou, California, Bengaluru
☆ Pfizer to replace migraine drug packaging over child safety concerns
  + stars: | 2023-03-16 | by ( ) www.reuters.com   time to read: +1 min
[1/2] The Pfizer logo is pictured on their headquarters building in the Manhattan borough of New York City, New York, U.S., November 9, 2020. REUTERS/Carlo Allegri/File PhotoCompanies Pfizer Inc FollowMarch 16 (Reuters) - Pfizer Inc (PFE.N) said on Thursday it was working on a new child-proof packaging for its migraine drug, Nurtec ODT, after safety concerns led to a recall alert from the U.S. Consumer Product Safety Commission (CPSC). Pfizer said it was developing a new packaging for the drug acquired through its $11.6 billion buyout of Biohaven Pharmaceutical Holding in 2022. As an interim measure, the company has instructed pharmacists to place the drug packet in a child-resistant vial before dispensing it to patients. The orally disintegrating tablets are used for the treatment of acute migraine and as preventive treatment for episodic migraine in adults.
☆ Pfizer looks past COVID with $43 bln deal for cancer drug innovator Seagen
  + stars: | 2023-03-13 | by ( Manas Mishra Michael Erman | Manas Mishra | Michael Erman | ) www.reuters.com   time to read: +3 min
Washington-based Seagen is a pioneer of antibody-drug conjugates, which work like "guided missiles" designed for a targeted destructive effect and spare healthy cells. The Pfizer logo is pictured on their headquarters building in the Manhattan borough of New York City, New York, U.S., November 9, 2020. The drugmaker expects more than $10 billion in sales from Seagen products in 2030, and another $15 billion from its other recent acquisitions. Pfizer said antitrust regulators could closely review the deal due to its size but eventually approve it. Pfizer rival Merck & Co Inc (MRK.N) and Seagen were in advanced deal talks last year but those reportedly collapsed over antitrust concerns.
☆ A new migraine medication is coming this summer — and it promises relief in just 15 minutes
  + stars: | 2023-03-11 | by ( Aidan Pollard | ) www.businessinsider.com   time to read: +2 min
The Food and Drug Administration on Friday approved a new nasal spray to treat migraines. The spray will be available in July and is designed to treat migraines in 15 minutes. The drug, which Pfizer acquired when it bought out Biohaven Pharmaceuticals last year for $11.6 billion, will provide an alternative to oral migraine medication, NBC News reported. The drug is not the first nasal medication of its kind, but it's anticipated to work more rapidly — the medication is intended to offer relief within 15 minutes, according to Pfizer. "Among my migraine patients, one of the most important attributes of an acute treatment option is how quickly it works."
☆ Drug companies face COVID cliff in 2023 as sales set to plummet
  + stars: | 2023-02-06 | by ( Michael Erman Patrick Wingrove | Michael Erman | Patrick Wingrove | ) www.reuters.com   time to read: +5 min
"When you think about traditional drug and vaccine development and longevity of sales, it's usually much more spread out," Morningstar analyst Damien Conover said. The sudden inflow of revenue should prod companies to strike deals and link up with new partners, he said. Vaccine maker Moderna also expects 2023 revenue to fall sharply. The company's only product - its messenger RNA COVID vaccine - pulled in around $18.4 billion in 2022. Eli Lilly and Co (LLY.N) made $2 billion in 2022 from monoclonal antibody COVID treatments and is not expecting any revenue from the business in 2023.
☆ The Covid sales boom is over for Pfizer
  + stars: | 2023-01-31 | by ( Paul R. La Monica | ) edition.cnn.com   time to read: +3 min
New York CNN —Pfizer generated nearly $57 billion in combined sales last year from its Comirnaty Covid-19 vaccine and Paxlovid antiviral pill. Pfizer (PFE) told Wall Street Tuesday that it expects Covid-related sales to plunge to $21.5 billion this year… below Wall Street’s forecasts. Pfizer noted that it now expects to sell just $13.5 billion of its vaccine and $8 billion of the Paxlovid pill this year. Wall Street was expecting vaccine revenue of $14.4 billion and $10.3 billion of Paxlovid for 2023, according to estimates tracked by Refinitiv. Pfizer reported Comirnaty sales of $37.8 billion last year and revenue of $18.9 billion from Paxlovid.
☆ Health-care stocks are looking good for 2023 and not just because the sector is a 'safe haven'
  + stars: | 2022-12-21 | by ( Christina Cheddar Berk | ) www.cnbc.com   time to read: +9 min
Investors looking for cover this year would have done well if they sought a safe haven in large-cap pharmaceutical stocks, a trend that is likely to continue into 2023. The Inflation Reduction Act provided some clarity around drug pricing that should help health-care stocks. The average price target, according to FactSet, is $62, or nearly 40% above the stock's closing price on Tuesday. Gene therapies in focus Investors will be closely watching the progress of several gene therapies, according to Phipps. "Yes, these are expensive therapies," Phipps said.
☆ Pfizer CEO reveals 2030 growth plan as company faces up to $18 billion revenue hit from generics
  + stars: | 2022-11-01 | by ( Spencer Kimball | ) www.cnbc.com   time to read: +3 min
Bourla said Pfizer is staring down an expected loss of between $16 billion and $18 billion in revenue from 2025 through 2030 as patent protections for some of its bestselling drugs expire. "We recognize that some are questioning Pfizer's longer-term growth prospects," Bourla told analysts during Pfizer's third-quarter earnings call Tuesday. Taken together, these five drugs represented about 40% of Pfizer's third-quarter revenue this year when the Covid vaccine and the antiviral treatment Paxlovid are excluded. Pfizer's RSV vaccine candidates for older adults and infants have the potential to generate billions in revenue, Bourla said. It would be the only RSV vaccine in the U.S. that protects infants by giving the shot to the mother, he said.
0 next >>
Total: 8